United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News Novartis gets Pluvicto EC approval for advanced prostate cancer Novartis has received the approval of the European Commission (EC) for Pluvicto (lutetium (177Lu) vipivotide tetraxetan), a targeted… byRaghuram KadariDecember 15, 2022